Healthcare / BiotechnologyUpdated 2026-05-10 22:07 UTC

NGNE stock hub

Neurogene Inc. has a live ticker hub with the latest available market, valuation, profitability, growth, ownership, and risk indicators.

Browse stocks

NGNEis not in this month’s coverageGet our monthly research letter — no spam

Fair value midpoint

n/a

Fair value pending

Upside to midpoint

n/a

Based on latest report

Confidence

n/a

Data quality and model convergence

Market cap

480.7M

NASDAQ

Market data

Live price

Current market quote for this ticker.

Current price

NGNE

In the news

Latest news · NGNE

Recent company headlines from major financial publishers.

—

Fetching the latest headlines.

—

Fetching the latest headlines.

—

Fetching the latest headlines.

Calendar

Next earnings

Upcoming earnings date and setup when available.

Upcoming

DateLoading

Window—

EPS estimate—

Revenue estimate—

Sector context

Where the current metrics sit

Percentiles come from the backend screener cohort cache for the ticker's country and sector.

Forward P/En/a

P25 12.3P50 18.4P75 33.1

Trailing P/En/a

P25 14.9P50 23.2P75 38.5

ROE-31.4

P25 -105.6P50 -46.5P75 -3.1

ROIC-21.6

P25 -63.1P50 -27.3P75 0.5

Benchmarks - 1M

S&P 500n/a

Nasdaq Compositen/a

Dow Jones Industrial Averagen/a

Russell 2000n/a

Indicator catalog

All NGNE market and fundamental indicators

A searchable catalog of the available market, valuation, profitability, growth, balance-sheet, ownership, and analyst metrics for this ticker.

Available fields

171

Groups with data

Currency

USD

Showing 171 of 171 available metrics for this ticker.

Profile and market data

Ticker identity, listing, currency, market cap, and source dates.

Metric	Value
Cik	0001404644
Company name	Neurogene Inc.
Country	United States
Country code	US
Cusip	64135M105
Employees	131
Employees Change	24%
Employees Change Percent	22.43
Enterprise value	$221.5M
Exchange	NASDAQ
Financial currency	USD
First seen	2026-05-09
Industry	Biotechnology
Isin	US64135M1053
Last refreshed	2026-05-10
Market cap	$480.7M
Market cap category	Small-Cap
Price	$30.78
Price currency	USD
Sector	Healthcare
Sic	2834
Symbol	NGNE
Website	https://www.neurogene.com

Valuation

Multiples, yields, enterprise-value ratios, and valuation checks.

Metric	Value
Earnings Yield	-18.8%
FCF yield	-16.3%
P/B ratio	1.8x

Profitability

Margins, returns on capital, cash conversion, and quality metrics.

Metric	Value
Gross Profit	$-74.9M
Net Income	$-90.4M
Net Income Growth Years	0%
Profit Per Employee	$-689,702
ROA	-20.66
ROCE	-37.92
ROE	-31.41
ROIC	-21.59

Growth

Revenue, earnings, cash-flow, and forward growth indicators.

Metric	Value
Cagr1y	122.2%
EPS Growth Years	3
Revenue Growth Years	0x

Financial strength

Debt, cash, solvency, accounting-quality, and balance-sheet signals.

Metric	Value
Assets	$288.6M
Cash	$269M
Current Assets	$271.8M
Current Liabilities	$16.4M
Debt	$9.9M
Debt Equity	$0.04
Equity	$264.9M
Interest Coverage	-20,641.6
Liabilities	$23.7M
Long Term Assets	$16.8M
Long Term Liabilities	$7.3M
Net Cash	$259.1M
Net Cash By Market Cap	$53.91
Net Cash Growth	-13.62%
Net Debt Equity	$-0.98
Tangible Book Value	$264.9M
Tangible Book Value Per Share	$17.1
WACC	15.38

Liquidity

Current-asset coverage and working-capital efficiency metrics.

Metric	Value
Current ratio	16.56
Net Working Capital	$-10.6M
Quick ratio	16.42
Working Capital	$255.4M

Dividends and buybacks

Dividend yield, payout, buybacks, and shareholder-yield indicators.

Metric	Value
Buyback Yield	-21.4%
Dividend Yield	0%

Performance and technicals

Returns, volatility, beta, momentum, RSI, and moving-average context.

Metric	Value
1Y total return	122.08%
200-day SMA	22.02
50-day SMA	23.55
50-day SMA vs 200-day SMA	50over200
All Time High	74.49
All Time High Change	-58.68%
All Time High Date	2024-11-11
All Time Low	6.88
All Time Low Change	347.71%
All Time Low Date	2025-04-08
ATR	2.17
Beta	2.08
Beta1y	1.84
Beta2y	2.92
Ch YTD	49.42
High	31.84
High52	37.27
High52 Date	2025-10-16
High52ch	-17.4%
Low	29.63
Low52	13.27
Low52 Date	2025-05-08
Low52ch	131.95%
Ma50ch	30.71%
Price vs 200-day SMA	39.78%
RSI	67.48
RSI Monthly	57
RSI Weekly	66.48
Sharpe ratio	1.25x
Sortino ratio	2.29
Total Return	-21.4%
Tr YTD	49.42
Tr1m	47.2%
Tr1w	14.64%
Tr3m	78.64%

Analyst estimates

Ratings, targets, revisions, and forward estimate fields.

Metric	Value
Analyst Count	7
Analyst Count Top	3
Analyst Price Target Top	$91.33
Analyst Ratings	Strong Buy
Analyst Ratings Top	Strong Buy
Earnings EPS Estimate	$-1.29
Operating Income	$-103.2M
Price target	$63.57
Price Target Change	$107
Price Target Change Top	$197

Ownership and float

Institutional, insider, float, short-interest, and share-count fields.

Metric	Value
Float	5,143,554%
Float Percent	32.94%
Net Borrowing	-61,000
Shares Insiders	10.18%
Shares Institutions	56.17%
Shares Out	15,615,786
Shares Qo Q	4.32%
Shares Yo Y	21.4%
Short Float	78%
Short Ratio	26.23
Short Shares	25.69

Other indicators

Additional ticker metrics that do not fit the primary research groupings yet.

Metric	Value
Adjusted FCF	$-92.5M
Average Volume	192,359.8x
Bv Per Share	17.1
CAPEX	$-1.2M
Ch1m	47.2
Ch1w	14.64
Ch1y	122.1
Ch3m	78.64
Ch6m	15.07
Change	-1.54%
Change From Open	1.02
Close	31.26
Days Gap	-2.53
Depreciation Amortization	3,092,000
Dollar Volume	5,197,018.3
Earnings Date	2026-05-22
Earnings Time	bmo
EBIT	$-103.2M
EBITDA	$-100.1M
EPS	$-4.24
F Score	1
FCF	$-78.4M
FCF EV Yield	-35.37x
FCF Per Share	$-5.02
Financing CF	30,428,000
Fiscal Year End	December
Founded	2,003
Investing CF	14,004,000
Is Primary Listing	1
Is Spac	No
Last Earnings Date	2026-03-24
Last Report Date	2025-12-31
Last Split Type	Never
Last10k Filing Date	2026-03-24
Ma150	22.81
Ma150ch	34.95%
Ma20	26.92
Ma20ch	14.33%
Net CF	-32,741,000
Next Earnings Date	2026-05-22
Open	30.47
Optionable	Yes
Position In Range	52.04
Post Close	30.78
Postmarket Change Percent	3.96
Postmarket Price	$32
Ppne	15,462,000
Price Date	2026-05-08
Ptbv Ratio	1.81
Relative Volume	0.88x
Share Based Comp	14,183,000
Tr6m	15.07%
Us State	New York
Volume	168,844

Fast facts

Decision checkpoints

A compact product layer over the same report payload.

Risk gate

n/a

Named kill scenarios are reviewed before any bullish rating can stand.

Moat score

n/a

Business quality stays separate from stock attractiveness.

Forward P/E

n/a

Valuation uses the full report model stack, not a single multiple.

Next action

Research pending

Final action steps are kept in the recommendation tab.

Income

Does NGNE pay a dividend?

Capital-return profile for this ticker.

Performance

NGNE stock returns vs the market

Total return (incl. dividends) compared to S&P 500.

Ownership

Who owns NGNE?

Insider, institutional, and short-interest positioning.

Institutional ownership

+56.2%

Float: +32.9% of shares outstanding

Insider ownership

+10.2%

Stake held by company insiders. Higher generally signals alignment.

Negative means the company is buying back shares.

Technical

NGNE momentum and risk profile

RSI, moving-average stack, beta, and risk-adjusted return.

RSI (14)

67.5

Neutral momentum band

Price vs 200-day MA

+39.8%

50/200-day relationship not available

Beta (5Y)

2.08

More volatile than the market

Sharpe ratio

1.25

Risk-adjusted return — higher is better; >1.0 is solid.

Questions

About NGNE

Hub-level FAQ points readers to the deeper analysis pages.

What is the current NGNE stock rating?

Neurogene Inc. is currently shown with the latest rating in the latest report. The hub links directly to the full analysis surface where the rating, fair-value bridge, risks, and scorecard are documented together.

Where can I read the full NGNE analysis?

The full report lives at /stocks/NGNE/analysis. The bare ticker page is a product hub that summarizes the latest read and sends readers into the relocated analysis tabs without making the analysis surface depend on the hub.

What fair-value range is used for NGNE?

The latest report frames NGNE around the latest fair-value range. Treat that range as the entry point, then check the valuation, sensitivity, and bear-case tabs before making an investment decision.

How often is the NGNE page updated?

The hub updates with the latest published stock report and live backend market data. The analysis pages remain reachable under /analysis, so a hub rollback does not remove the report reader.